Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Mark L. Smith is active.

Publication


Featured researches published by Mark L. Smith.


Vaccine | 2003

Structural characterization of plant-derived hepatitis B surface antigen employed in oral immunization studies

Mark L. Smith; Lizabeth Richter; Charles J. Arntzen; Michael L. Shuler; Hugh S. Mason

Several subunit vaccine antigens have been successfully expressed in plants and recently the hepatitis B surface antigen (HBsAg), expressed in potatoes, was shown to be orally immunogenic in animal studies. However, to date, a detailed analysis of the plant-derived antigen is lacking. Herein, we comprehensively characterize the structure and post-translational processing of HBsAg from potato tuber and two plant cell suspension cultures. The HBsAg was found to accumulate intracellularly as tubular structures, with a complex size distribution, differing substantially from the virus-like particle (VLP) preparations of the current commercial vaccines. Extensive disulfide-bond cross-linking, which is important for immunogenicity, was evident and 21-37% of total HBsAg protein displayed epitopes which correlate with vaccine potency. The significance of these results with regard to the production of cost-effective orally delivered vaccines is discussed.


Biotechnology Progress | 2002

Factors important in the extraction, stability and in vitro assembly of the hepatitis B surface antigen derived from recombinant plant systems.

Mark L. Smith; Mark E. Keegan; Hugh S. Mason; Michael L. Shuler

The expression of vaccine antigens in edible plant material together with their delivery by the oral route constitutes a powerful paradigm, with the potential to dramatically reduce the cost of vaccine production and administration, in addition to improving distribution and patient compliance. These products will be subject to many of the same regulations applied to current injectable vaccines, so reliable methods to quantify antigen and ensure stability in crude plant extracts are required. As a model system the hepatitis B surface antigen (HBsAg) was expressed in soybean and tobacco cell cultures. This complex antigen consists of membrane‐associated small surface antigen proteins (p24s), disulfide cross‐linked to yield dimers and higher multimers. Although the total p24s extracted from plant cells was relatively unaffected by detergent concentration, the quantification of antigenically reactive product depended strongly on the ratio of detergent to cell concentration. Furthermore, 1–20% w/v sodium ascorbate improved the measured levels of monoclonal‐reactive antigen 4‐ to 12‐fold. Detergent also influenced antigen stability in cell lysates stored at 4 °C; under optimum conditions stability was maintained for at least 1 month, whereas excess detergent rendered the antigen susceptible to proteolytic degradation. This proteolysis could be counteracted by the addition of skim milk or its protein component, which stabilized antigenically reactive p24s for up to 2 months. The immunologically relevant epitopes of HBsAg are critically dependent on disulfide bonding. By altering the sodium ascorbate concentration or buffer pH the proportion of HBsAg displaying the monoclonal reactive epitopes was increased between 8‐ and 20‐fold. In addition, under certain conditions the dimerized p24s could be converted to oligomeric aggregates, resembling the form of the serum‐derived antigen. These simple in vitro manipulations, compatible with the goal of a minimally processed oral vaccine, may prove valuable in increasing the immunogenicity of the plant‐derived antigen.


Virology | 2006

Modified tobacco mosaic virus particles as scaffolds for display of protein antigens for vaccine applications

John A. Lindbo; Kenneth E. Palmer; Mark L. Smith


Biotechnology and Bioengineering | 2002

Hepatitis B surface antigen (HBsAg) expression in plant cell culture: Kinetics of antigen accumulation in batch culture and its intracellular form.

Mark L. Smith; Hugh S. Mason; Michael L. Shuler


Vaccine | 2006

Protection of rabbits against cutaneous papillomavirus infection using recombinant tobacco mosaic virus containing L2 capsid epitopes

Kenneth E. Palmer; Ann L. Benko; Sarah A. Doucette; Terri I. Cameron; Tiffany Foster; Kathleen M. Hanley; Alison A. McCormick; Michael McCulloch; Gregory P. Pogue; Mark L. Smith; Neil D. Christensen


Vaccine | 2006

TMV-peptide fusion vaccines induce cell-mediated immune responses and tumor protection in two murine models

Alison A. McCormick; Tina A. Corbo; Sherri Wykoff-Clary; Long V. Nguyen; Mark L. Smith; Kenneth E. Palmer; Gregory P. Pogue


Virology | 2007

Assembly of trans-encapsidated recombinant viral vectors engineered from Tobacco mosaic virus and Semliki Forest virus and their evaluation as immunogens

Mark L. Smith; Tina A. Corbo; Jacqueline Bernales; John A. Lindbo; Gregory P. Pogue; Kenneth E. Palmer; Alison A. McCormick


Archive | 2003

Flexible vaccine assembly and vaccine delivery platform

Alison A. McCormick; Mark L. Smith; Kenneth E. Palmer; John A. Lindbo; Long V. Nguyen; Gregory P. Pogue


Archive | 2003

Mismatch endonucleases and methods of use

Hal S. Padgett; Andrew A. Vaewhongs; Fakhrieh S. Vojdani; Mark L. Smith; John A. Lindbo; Wayne P. Fitzmaurice


Archive | 2004

Neutralizing epitope-based growth enhancing vaccine

David E. Junker; Mark D. Cochran; Mark L. Smith; Kenneth E. Palmer; Gregory P. Pogue

Collaboration


Dive into the Mark L. Smith's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Wayne P. Fitzmaurice

R. J. Reynolds Tobacco Company

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Hugh S. Mason

Arizona State University

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge